• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr William "Andy" Nish on Considering Adherence When Prescribing Biologics to Patients With Asthma

Video

Switching patients with asthma to a biologic medication purely because that patient is not adherent to inhaled medications gets in the way of a physician's goal of being good stewards of patient care and finances, said William "Andy" Nish, MD.

William "Andy" Nish, MD, is a medical director and provider with a specialty in allergy and immunology at Northeast Georgia Physicians Group in Gainesville, Georgia.

Transcript:

If nonadherence with inhaled corticosteroids has been a factor for the patient, should that influence whether the patient should move to a biologic?

Certainly, we would want them to be adherent as the most important thing. Partially because if we're going to be good stewards of care and finances and somebody is not going to take their basic medicine and they're going to switch to a medicine that's $20,000 or $30,000 a year just because they're not taking their inhaler, I have a hard time with that. So, definitely adherence or compliance with their routine medicines should come first. And, in an ideal world, to put them on such an expensive medicine as a biologic just because they won’t take their inhaled steroid is something I would struggle with.

Related Videos
Pat Van Burkleo
Jeff Stark, MD, vice president, head of medical immunology, UCB
Robert Groves, MD
Screenshot of Raajit Rampal, MD, PhD
 Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh
Dr Padma Sripada, Columbia Internal Medicine
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
dr amy paller
Shawn Kwatra, MD, dermatologist, John Hopkins University
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.